{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Other+Solid+Tumor+Cancers",
    "query": {
      "condition": "Other Solid Tumor Cancers"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 381,
    "total_pages": 39,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Other+Solid+Tumor+Cancers&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-07-22T14:57:08.139Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05071183",
      "title": "A Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "KRAS Mutation-Related Tumors",
        "Metastatic Solid Tumor",
        "Advanced Solid Tumor"
      ],
      "interventions": [
        {
          "name": "TPX-0005",
          "type": "DRUG"
        },
        {
          "name": "Trametinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Turning Point Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2021-09-23",
      "completion_date": "2023-03-01",
      "has_results": true,
      "last_update_posted_date": "2024-04-02",
      "last_synced_at": "2026-07-22T14:57:08.139Z",
      "location_count": 6,
      "location_summary": "California City, California • Denver, Colorado • Nashville, Tennessee + 2 more",
      "locations": [
        {
          "city": "California City",
          "state": "California"
        },
        {
          "city": "California City",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05071183"
    },
    {
      "nct_id": "NCT07356453",
      "title": "A Study of PARG Inhibitor FORX-428 in Patients With Advanced Solid Tumors.",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumors"
      ],
      "interventions": [
        {
          "name": "FORX-428",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "FoRx Therapeutics AG",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2025-07-22",
      "completion_date": "2028-04",
      "has_results": false,
      "last_update_posted_date": "2026-01-21",
      "last_synced_at": "2026-07-22T14:57:08.139Z",
      "location_count": 8,
      "location_summary": "Palo Alto, California • San Francisco, California • Grand Rapids, Michigan + 5 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07356453"
    },
    {
      "nct_id": "NCT00019760",
      "title": "Isolated Hepatic Perfusion With Melphalan Followed By Chemotherapy in Treating Patients With Unresectable Colorectal Cancer That is Metastatic to the Liver",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Colon Cancer",
        "Liver Metastases",
        "Stage IV Rectal Cancer",
        "Recurrent Rectal Cancer",
        "Stage IV Colon Cancer"
      ],
      "interventions": [
        {
          "name": "floxuridine",
          "type": "DRUG"
        },
        {
          "name": "leucovorin calcium",
          "type": "DRUG"
        },
        {
          "name": "melphalan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institutes of Health Clinical Center (CC)",
      "sponsor_class": "NIH",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": null,
      "start_date": "1999-04",
      "completion_date": "2002-03",
      "has_results": false,
      "last_update_posted_date": "2023-10-31",
      "last_synced_at": "2026-07-22T14:57:08.139Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00019760"
    },
    {
      "nct_id": "NCT05551117",
      "title": "A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Castration-Resistant Prostatic Cancer",
        "Androgen-Independent Prostatic Cancer",
        "Androgen-Insensitive Prostatic Cancer",
        "Androgen-Resistant Prostatic Cancer",
        "Hormone Refractory Prostatic Cancer",
        "Anal Cancer",
        "Anal Neoplasm",
        "Carcinoma, Squamous Cell of Head and Neck",
        "Head and Neck Squamous Cell Carcinoma",
        "Laryngeal Squamous Cell Carcinoma",
        "Oral Squamous Cell Carcinoma",
        "Malignant Melanoma",
        "Melanoma",
        "Non-small Cell Lung Cancer",
        "Non-small Cell Carcinoma",
        "Small-cell Lung Cancer",
        "Small Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "vobramitamab duocarmazine 2.0 mg (Arm A)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "vobramitamab duocarmazine 2.7 mg (Arm B)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "vobramitamab duocarmazine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Abiraterone",
          "type": "DRUG"
        },
        {
          "name": "Enzalutamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "MacroGenics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 192,
      "start_date": "2023-06-13",
      "completion_date": "2025-01-23",
      "has_results": true,
      "last_update_posted_date": "2026-02-09",
      "last_synced_at": "2026-07-22T14:57:08.139Z",
      "location_count": 14,
      "location_summary": "Fountain Valley, California • Los Angeles, California • Jacksonville, Florida + 11 more",
      "locations": [
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Orange City",
          "state": "Florida"
        },
        {
          "city": "Covington",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05551117"
    },
    {
      "nct_id": "NCT02123862",
      "title": "Cultured Circulating Tumor Cells in Prostate and Other Cancers",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Oscar Goodman, Jr.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 220,
      "start_date": "2014-04",
      "completion_date": "2018-04",
      "has_results": false,
      "last_update_posted_date": "2015-01-19",
      "last_synced_at": "2026-07-22T14:57:08.139Z",
      "location_count": 1,
      "location_summary": "Las Vegas, Nevada",
      "locations": [
        {
          "city": "Las Vegas",
          "state": "Nevada"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02123862"
    },
    {
      "nct_id": "NCT02452424",
      "title": "A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Melanoma",
        "Non-small Cell Lung Cancer",
        "Squamous Cell Carcinoma of the Head and Neck",
        "Gastrointestinal Stromal Tumor (GIST)",
        "Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "PLX3397",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Daiichi Sankyo",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 78,
      "start_date": "2015-07-02",
      "completion_date": "2018-10-12",
      "has_results": true,
      "last_update_posted_date": "2020-03-05",
      "last_synced_at": "2026-07-22T14:57:08.139Z",
      "location_count": 12,
      "location_summary": "Scottsdale, Arizona • Greenbrae, California • Los Angeles, California + 7 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Greenbrae",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02452424"
    },
    {
      "nct_id": "NCT03681951",
      "title": "First-time-in-human (FTIH) Study of GSK3145095 Alone and in Combination With Other Anticancer Agents in Adults With Advanced Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neoplasms, Pancreatic"
      ],
      "interventions": [
        {
          "name": "GSK3145095",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 8,
      "start_date": "2018-11-16",
      "completion_date": "2019-08-13",
      "has_results": true,
      "last_update_posted_date": "2020-07-31",
      "last_synced_at": "2026-07-22T14:57:08.139Z",
      "location_count": 6,
      "location_summary": "Indianapolis, Indiana • New York, New York • Philadelphia, Pennsylvania + 1 more",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03681951"
    },
    {
      "nct_id": "NCT03144661",
      "title": "An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hepatocellular Carcinoma (HCC)",
        "Cholangiocarcinoma",
        "Esophageal Cancer",
        "Nasopharyngeal Cancer",
        "Ovarian Cancer",
        "Solid Tumors"
      ],
      "interventions": [
        {
          "name": "INCB062079",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Incyte Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2017-05-25",
      "completion_date": "2020-06-10",
      "has_results": false,
      "last_update_posted_date": "2025-10-21",
      "last_synced_at": "2026-07-22T14:57:08.139Z",
      "location_count": 3,
      "location_summary": "Birmingham, Alabama • New York, New York • Toledo, Ohio",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Toledo",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03144661"
    },
    {
      "nct_id": "NCT01528774",
      "title": "Culture and Characterization of Circulating Tumor Cells (CTC) in Melanoma and Other Cancers",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "Blood Draw",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Wolfram Samlowski",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 150,
      "start_date": "2016-06",
      "completion_date": "2016-06",
      "has_results": false,
      "last_update_posted_date": "2017-07-26",
      "last_synced_at": "2026-07-22T14:57:08.139Z",
      "location_count": 1,
      "location_summary": "Las Vegas, Nevada",
      "locations": [
        {
          "city": "Las Vegas",
          "state": "Nevada"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01528774"
    },
    {
      "nct_id": "NCT00765973",
      "title": "Topotecan Liposomes Injection for Small Cell Lung Cancer (SCLC), Ovarian Cancer and Other Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Small Cell Lung Cancer",
        "Ovarian Cancer",
        "Solid Tumors"
      ],
      "interventions": [
        {
          "name": "Topotecan Liposomes Injection (TLI)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Spectrum Pharmaceuticals, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "2008-11-10",
      "completion_date": "2010-06-30",
      "has_results": false,
      "last_update_posted_date": "2020-11-13",
      "last_synced_at": "2026-07-22T14:57:08.139Z",
      "location_count": 2,
      "location_summary": "Detroit, Michigan • San Antonio, Texas",
      "locations": [
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00765973"
    }
  ]
}